The Evaluation of Beat Blocker and Calcium Antagonist Drugs: Developments in Cardiovascular Medicine, cartea 18
Editat de J. Morganroth, E. Neil Mooreen Limba Engleză Paperback – 2 noi 2011
Din seria Developments in Cardiovascular Medicine
- 5% Preț: 1484.50 lei
- 5% Preț: 375.17 lei
- 5% Preț: 354.10 lei
- 5% Preț: 1390.24 lei
- 5% Preț: 368.85 lei
- 5% Preț: 1076.01 lei
- 5% Preț: 1409.19 lei
- 5% Preț: 369.22 lei
- 5% Preț: 360.97 lei
- 5% Preț: 372.61 lei
- 5% Preț: 2074.57 lei
- 5% Preț: 359.89 lei
- 5% Preț: 359.18 lei
- 5% Preț: 363.65 lei
- 5% Preț: 363.50 lei
- 5% Preț: 767.35 lei
- 5% Preț: 698.75 lei
- 5% Preț: 1076.01 lei
- 5% Preț: 367.95 lei
- 5% Preț: 365.99 lei
- 5% Preț: 709.31 lei
- 5% Preț: 1081.74 lei
- 5% Preț: 2074.21 lei
- 5% Preț: 701.61 lei
- 5% Preț: 364.56 lei
- 5% Preț: 707.73 lei
- 5% Preț: 646.75 lei
- 5% Preț: 367.79 lei
- 5% Preț: 1394.36 lei
- 5% Preț: 700.90 lei
- 5% Preț: 774.69 lei
- 5% Preț: 706.10 lei
- 5% Preț: 3120.75 lei
- 5% Preț: 1389.50 lei
- 5% Preț: 768.78 lei
- 5% Preț: 700.18 lei
- 5% Preț: 363.29 lei
- 5% Preț: 368.67 lei
- 5% Preț: 647.49 lei
- 5% Preț: 360.97 lei
Preț: 368.15 lei
Preț vechi: 387.52 lei
-5% Nou
Puncte Express: 552
Preț estimativ în valută:
70.48€ • 73.26$ • 58.43£
70.48€ • 73.26$ • 58.43£
Carte tipărită la comandă
Livrare economică 06-20 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789400975637
ISBN-10: 9400975635
Pagini: 424
Ilustrații: 419 p.
Dimensiuni: 155 x 235 x 22 mm
Greutate: 0.59 kg
Ediția:Softcover reprint of the original 1st ed. 1982
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Cardiovascular Medicine
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9400975635
Pagini: 424
Ilustrații: 419 p.
Dimensiuni: 155 x 235 x 22 mm
Greutate: 0.59 kg
Ediția:Softcover reprint of the original 1st ed. 1982
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Cardiovascular Medicine
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
Beta-Adrenoceptor Blocking Agents: Historical Perspectives.- The Clinical Relevance of Beta-Receptor Blockade, Intrinsic Sympathomimetic Activity and Membrane Depressant Action.- Pharmacokinetics and Pharmacodynamics of Beta Blockers.- Importance of Alpha Blocking and Vasodilator Effects of Beta Blocking Agents.- Are Animal Models Useful in Determining if All Beta-Blocking Agents Are the Same.- Moderator’s Comments on Beta Blocking Drugs.- General Group Discussion: Are All Beta Blocking Agents the same.- How to Define Beta Blocker Usefulness in Hypertension Is Ambulatory Monitoring Necessary.- Evaluation of Beta Blocking Agents in the Treatment of Angina Pectoris Due to Coronary Artery Disease.- Beta Blocking Agents in the Treatment of Ventricular Arrhythmias.- How to Define Beta Blocker Usefulness in Supraventricular Arrhythmias.- How to Define Beta Blocker Usefulness in Hypertension, Angina and Arrhythmias: An Overview.- General Group Discussion: How to Define Beta Blocker Usefulness.- Comparative Safety of Beta Blocking Drugs.- Current Problems in the Evaluation of New Beta Blocking Agents.- General Group Discussion: Problems in Study Design.- Remarks by Commissioner of Food and Drugs.- Beta Blocker in Sudden Death Prevention.- Do Beta-Blockers Prolong Life.- Clinical Trials to Prevent Sudden Death: what Are the Problems in Study Design.- Who Should Fund Clinical Trials.- General Group Discussion: Beta Blockers in Sudden Death Prevention.- Calcium Channel Blockers/Historical Perspectives.- Comparative Clinical Pharmacology of Slow Channel Blocking Agents.- The Electrophysiologic Differences of Calcium Antagonist Drugs.- Clinical Differences Between the Calcium Channel Blocking Agents.- General Group Discussion: Calcium Antagonists.- How to Define Controlled Studiesin Coronary Artery Spasm.- Calcium Entry Blocking Agents: How to Define Controlled Studies in Patients with Arrhythmias.- Evaluation of Beta Blockers and Calcium Antagonists in the Treatment of Hypertrophic Cardiomyopathy.- Determination of the Safety of Calcium Antagonists in Combination with Beta-Adrenergic Blocking Agents — the Case for Circumscribed Clinical Trials.- General Group Discussion: How to Define Controlled Studies.- List of Participants.